Bioavailability of oral melatonin in humans. 1984

F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman

We administered crystalline melatonin (80 mg) in gelatin capsules to 5 young male volunteers and measured serum and urinary melatonin levels at intervals. Changes in serum melatonin levels were best described by a biexponential equation with an absorption constant (ka) of 1.72 h-1 (half-life = 0.40 h) and an elimination constant (ke1) of 0.87 h-1 (half-life = 0.80 h). Peak serum melatonin levels, ranging from 350 to 10,000 times those occurring physiologically at nighttime, were observed 60-150 min after its administration, remaining stable for approximately 1.5 h. The fraction of ingested melatonin that was absorbed, estimated from the area under the curve describing serum melatonin concentrations as a function of time after melatonin administration (the concentration-time curve), varied by 25-fold among subjects. 3 additional volunteers received three melatonin-containing capsules (80 mg each) at 60-min intervals. This regimen extended the duration of elevated serum melatonin levels to 4-6 h. Melatonin excretion closely paralleled serum melatonin levels until 9 h after the hormone's administration, after which urinary levels tended to be higher than those predicted from serum levels. However, the area under the concentration-time curve for serum melatonin correlated well (r = 0.96) with the cumulative melatonin excretion during the initial 15 h after melatonin's administration, indicating that either approach can be used to estimate the absorption of orally administered melatonin.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
April 1997, The New England journal of medicine,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
July 2000, Journal of clinical pharmacology,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
January 2000, Biopharmaceutics & drug disposition,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
January 2000, Clinical pharmacology and therapeutics,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
March 2009, Neuro endocrinology letters,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
June 2018, Journal of analytical toxicology,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
December 1994, Arzneimittel-Forschung,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
July 1983, Journal of pharmaceutical sciences,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
June 1994, Arzneimittel-Forschung,
F Waldhauser, and M Waldhauser, and H R Lieberman, and M H Deng, and H J Lynch, and R J Wurtman
May 1992, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!